Fidelity International’s Ascendis Pharma A/S ASND Stock Holding History

Fidelity International’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$92.2M	Sell	345,567 -101,854	-23%	-$23.8M	0.07%	251
2026 Q1	$102M	Sell	447,421 -31,220	-7%	-$7M	0.08%	233
2025 Q4	$102M	Buy	478,641 +19,301	+4%	+$3.99M	0.08%	233
2025 Q3	$91.3M	Sell	459,340 -4,756	-1%	-$887K	0.07%	239
2025 Q2	$80.1M	Buy	464,096 +1,730	+0.4%	+$282K	0.07%	256
2025 Q1	$72.1M	Sell	462,366 -266,909	-37%	-$38.1M	0.07%	266
2024 Q4	$100M	Buy	729,275 +89,016	+14%	+$11.7M	0.09%	217
2024 Q3	$95.6M	Buy	640,259 +197,751	+45%	+$26.7M	0.09%	234
2024 Q2	$60.3M	Buy	442,508 +431,781	+4,025%	+$58.7M	0.06%	284
2024 Q1	$1.62M	Buy	10,727 +4,729	+79%	+$675K	﹤0.01%	694
2023 Q4	$755K	Buy	+5,998	New	+$598K	﹤0.01%	719
2023 Q2	–	Sell	-45,000	Closed	-$4.82M	–	809
2023 Q1	$4.82M	Sell	45,000 -65	-0.1%	-$7.44K	0.01%	573
2022 Q4	$5.5M	Buy	+45,065	New	+$5.23M	0.01%	572
2021 Q4	–	Sell	-669	Closed	-$107K	–	812
2021 Q3	$107K	Sell	669 -134,325	-100%	-$18.4M	﹤0.01%	797
2021 Q2	$17.8M	Sell	134,994 -36,889	-21%	-$4.92M	0.02%	473
2021 Q1	$22.2M	Buy	171,883 +8,359	+5%	+$1.27M	0.03%	425
2020 Q4	$27.3M	Buy	163,524 +68,607	+72%	+$11.3M	0.03%	369
2020 Q3	$14.6M	Buy	94,917 +124	+0.1%	+$17.8K	0.02%	440
2020 Q2	$14M	Sell	94,793 -97,171	-51%	-$13.3M	0.02%	432
2020 Q1	$21.6M	Buy	191,964 +22,328	+13%	+$2.9M	0.04%	350
2019 Q4	$23.6M	Sell	169,636 -14,967	-8%	-$1.66M	0.03%	377
2019 Q3	$17.7M	Sell	184,603 -29,575	-14%	-$3.3M	0.03%	397
2019 Q2	$24.7M	Sell	214,178 -34,521	-14%	-$4.13M	0.04%	344
2019 Q1	$29.3M	Buy	248,699 +121,912	+96%	+$10.7M	0.05%	317
2018 Q4	$7.94M	Buy	126,787 +13,669	+12%	+$859K	0.01%	462
2018 Q3	$8.02M	Buy	113,118 +78,474	+227%	+$5.4M	0.01%	508
2018 Q2	$2.31M	Buy	+34,644	New	+$2.28M	﹤0.01%	595

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Fidelity International's ASND Position: Q2 2026 in Review

Fidelity International reduced its Ascendis Pharma A/S (ASND) stake by 23% in Q2 2026, selling an estimated $23.8M and leaving 345,567 shares worth $92.2M. The position accounts for 0.07% of the portfolio, ranked #251.

Fidelity International first reported a position in ASND in Q2 2018 and has held it in 27 quarters since. The position peaked at $102M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Fidelity International held 345,567 shares of Ascendis Pharma A/S worth $92.2M as of Q2 2026.
Fidelity International sold 101,854 Ascendis Pharma A/S shares in Q2 2026, an estimated $23.8M.
Ascendis Pharma A/S made up 0.07% of Fidelity International's portfolio in Q2 2026, its #251 holding.
Fidelity International first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 27 quarters since.
Fidelity International's Ascendis Pharma A/S position peaked at $102M in Q1 2026.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.